NVTS

Navitas Semiconductor (NVTS) partnered with NVIDIA to develop a 24-kW power delivery board that converts 800V DC to 12V DC in a single stage, eliminating intermediate conversion steps. This advancement supports NVTS' 800V strategy as AI data centers demand more efficient power solutions. However, NVTS faces strong competition from ON Semiconductor and STMicroelectronics, and trades at a significantly elevated valuation with a Zacks Rank #3 (Hold) rating.

Navitas Semiconductor completed its acquisition of Claros, adding intelligent voltage regulator (IVR) technology to its GaN and high-voltage SiC portfolio. The deal strengthens Navitas' grid-to-xPU power delivery capabilities for AI infrastructure, addressing the final stage of power delivery to processors. However, NVTS trades at a significantly elevated valuation of 48.71X forward P/S versus the industry average of 5.26X, and faces intense competition from ON Semiconductor and STMicroelectronics in the AI data center power market.

Navitas Semiconductor has rallied 72.2% YTD, benefiting from strong AI data center demand for efficient power solutions and 800V adoption opportunities. However, the company faces near-term headwinds from faster-than-expected mobile revenue declines and trades at a premium valuation (50.55X P/S) compared to industry peers. Analysts recommend a Hold rating.

Lumentum Holdings (LITE) and Navitas Semiconductor (NVTS) are two key players benefiting from AI data center demand. Lumentum is experiencing surging demand for optical components with 109% YoY revenue growth and strong earnings momentum, while Navitas faces ongoing losses and execution risks despite ramping AI power programs. Lumentum is rated as the stronger investment opportunity with a Zacks Rank #2 (Buy) versus Navitas's Rank #3 (Hold).

Navitas Semiconductor has received U.S. Army validation for a 10-kV silicon carbide program, which could expand into grid and industrial power systems. However, investors are still waiting to see commercial payoff from the technology.

The article highlights four high-risk, high-reward stocks: Agios Pharmaceuticals awaiting FDA approval for mitapivat to treat sickle cell disease; Navitas Semiconductor pivoting toward AI data centers and high-power chips; Joby Aviation developing eVTOL transportation services with autonomous capabilities; and Viking Therapeutics developing obesity drug VK2735 with potential in a multi-billion dollar market. All require patience but offer significant upside if their respective catalysts materialize.